Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt
By David Sachs
Grifols shares jumped Friday after the pharmaceutical company said it will sell a sizable stake in a Chinese medicine developer for $1.76 billion in order to pay down debt.
The Barcelona-based group said Friday that it will sell a roughly 20% stake in Shanghai RAAS Blood Products to Haier Group, a Chinese appliance company with a biomedical unit, for 12.5 billion Chinese yuan. Grifols will use the proceeds to pay off debt, it said.
At 1417 GMT, shares in Grifols were up 9.4% to EUR15.57, having risen as high as EUR15.92.
Grifols will still hold an approximate stake of 6.6% in Shanghai RAAS and a seat on its board of directors following the transaction, which is subject to standard regulatory closing conditions, the company said.
"Grifols and Haier envision broad cooperation to contribute to China's growing and developing healthcare system," Grifols said.
Shanghai RAAS's 45% stake in Grifols Diagnostic Solutions and 40% voting rights in the company will remain the same.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 29, 2023 09:44 ET (14:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks